England begins nationwide blood test trial for early cancer detection

A major clinical trial launched in England aims to verify whether routine blood tests can help general practitioners diagnose cancer months earlier. The initiative marks the first national effort to use liquid biopsy technology within primary care settings to catch disease in its most treatable stages.

The study will enroll more than 20,000 patients across at least 200 GP practices in the National Health Service. Participants must be aged 45 or older and present with abdominal complaints such as persistent bloating or discomfort. Researchers will compare standard diagnostic pathways against results from the new blood screening tools.

Developed by the University of Birmingham and its partners, the tests analyze protein markers and use artificial intelligence to detect signs of 14 specific cancers. The panel includes prostate, ovarian, bowel, pancreatic, stomach, and liver cancer. The technology is designed to pinpoint the organ of origin for detected abnormalities.

Britain currently records some of the highest cancer mortality rates per capita among OECD nations. Many of the cancers included in this trial are typically found at late stages when treatment options are more limited and survival odds are lower. The trial measures whether earlier intervention through blood screening translates to better patient outcomes.

The project will assess how effectively the tests support a doctor's clinical judgment before any decision is made to expand the program nationally. GPs will receive the results alongside their standard evaluations. The data collected will determine if the method provides a reliable advantage in identifying patients who require urgent treatment.